Back to Search
Start Over
CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival.
- Source :
- PLoS ONE; Apr2013, Vol. 8 Issue 4, p1-11, 11p
- Publication Year :
- 2013
-
Abstract
- CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8<superscript>+</superscript> cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4<superscript>+</superscript> or CD8<superscript>+</superscript> T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8<superscript>+</superscript> T cell proliferation and IFN-γ production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4<superscript>−/−</superscript>, CD28<superscript>−/−</superscript> knockout and CTLA4Ig treated WT recipients, but not in WT or CD8<superscript>−/−</superscript> knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8<superscript>+</superscript> T cell proliferation, effector/memory responses and alloreactive IFN-γ production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8<superscript>+</superscript> alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 8
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- 87677423
- Full Text :
- https://doi.org/10.1371/journal.pone.0060391